News articles about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have trended positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical Corporation earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.4310044151601 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Nymox Pharmaceutical Corporation (NASDAQ NYMX) opened at 3.82 on Friday. The stock’s market cap is $200.04 million. Nymox Pharmaceutical Corporation has a 52 week low of $2.67 and a 52 week high of $5.10. The stock’s 50 day moving average price is $3.67 and its 200 day moving average price is $3.87.

Separately, ValuEngine upgraded Nymox Pharmaceutical Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 11th.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at

In other news, Director James George Robinson bought 11,500 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The shares were purchased at an average price of $4.00 per share, with a total value of $46,000.00. Following the purchase, the director now owns 3,046,550 shares in the company, valued at $12,186,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have purchased 49,500 shares of company stock worth $189,660. 54.00% of the stock is owned by corporate insiders.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with's FREE daily email newsletter.